LUMO

Lumos Pharma (LUMO)

Lumos Pharma Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:LUMO

1 2 3 4 5 6 7 8 9 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/08	05 : 08	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LUMO	Lumos Pharma Inc
2024/06/08	05 : 07	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LUMO	Lumos Pharma Inc
2024/06/08	05 : 07	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LUMO	Lumos Pharma Inc
2024/06/08	05 : 07	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LUMO	Lumos Pharma Inc
2024/06/08	05 : 07	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LUMO	Lumos Pharma Inc
2024/06/08	05 : 06	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LUMO	Lumos Pharma Inc
2024/06/06	05 : 09	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LUMO	Lumos Pharma Inc
2024/06/05	06 : 02	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LUMO	Lumos Pharma Inc
2024/06/04	22 : 00	GlobeNewswire Inc.	Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024	NASDAQ:LUMO	Lumos Pharma Inc
2024/05/21	05 : 05	GlobeNewswire Inc.	Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024	NASDAQ:LUMO	Lumos Pharma Inc
2024/05/15	22 : 57	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LUMO	Lumos Pharma Inc
2024/05/15	05 : 15	GlobeNewswire Inc.	Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results	NASDAQ:LUMO	Lumos Pharma Inc
2024/05/10	03 : 51	GlobeNewswire Inc.	Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024	NASDAQ:LUMO	Lumos Pharma Inc
2024/04/19	05 : 05	GlobeNewswire Inc.	Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings	NASDAQ:LUMO	Lumos Pharma Inc
2024/03/20	21 : 00	GlobeNewswire Inc.	Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042	NASDAQ:LUMO	Lumos Pharma Inc
2024/03/08	06 : 48	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:LUMO	Lumos Pharma Inc
2024/03/08	06 : 44	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LUMO	Lumos Pharma Inc
2024/03/08	06 : 01	GlobeNewswire Inc.	Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update	NASDAQ:LUMO	Lumos Pharma Inc
2024/02/26	23 : 00	GlobeNewswire Inc.	Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024	NASDAQ:LUMO	Lumos Pharma Inc
2024/02/08	07 : 22	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LUMO	Lumos Pharma Inc
2024/02/07	06 : 02	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:LUMO	Lumos Pharma Inc
2024/02/06	07 : 55	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LUMO	Lumos Pharma Inc
2024/02/06	07 : 54	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LUMO	Lumos Pharma Inc
2024/02/06	07 : 53	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LUMO	Lumos Pharma Inc
2024/02/06	07 : 52	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LUMO	Lumos Pharma Inc
2024/02/06	07 : 51	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:LUMO	Lumos Pharma Inc
2024/02/06	06 : 05	GlobeNewswire Inc.	Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference	NASDAQ:LUMO	Lumos Pharma Inc
2024/01/11	09 : 03	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:LUMO	Lumos Pharma Inc
2024/01/05	06 : 34	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:LUMO	Lumos Pharma Inc
2024/01/05	06 : 05	GlobeNewswire Inc.	Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer	NASDAQ:LUMO	Lumos Pharma Inc